Combination of intranasal dexmedetomidine and oral midazolam in autism children undergoing computer tomographic: a prospective randomized controlled trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-14004761

Enrollment

Unknown

Registered

2014-05-29

Start date

2014-06-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

autism

Interventions

Two groups:oral placebo or oral midazolam

Eligibility

Sex/Gender

All

Age

1 Years to 18 Years

Inclusion criteria

Inclusion criteria: Children who met DSM-IV criteria for autistic spectrum disorders of ASA physical status I-II, aged between 2 and 18 years, requiring to undergo computer tomographic examination will be enrolled in this prospective randomized controlled trial.

Exclusion criteria

Exclusion criteria: Exclusion criteria include organ dysfunction,known allergy or hypersensitive reaction to dexmedetomidine and midazolam.

Design outcomes

Primary

Measure	Time frame
satisfactory sedation rate;onset time;duration of examination;wakeup time;	—

Countries

China

Contacts

Public ContactLi Bilian

Guangzhou Women and Children's Medical Centre

13570226780@126.com+86 13570226780

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026